-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89

Benzinga·09/24/2026 12:56:18
Listen to the news
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $75 to $89.